{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:59:31Z","timestamp":1776092371186,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Shandong Province Youth Fund","award":["ZR2020QH124"],"award-info":[{"award-number":["ZR2020QH124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-026-04168-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:26:37Z","timestamp":1772774797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protective effects of diosgenin against non-alcoholic fatty liver disease through inhibiting the STING-dependent inflammatory pathway"],"prefix":"10.1186","volume":"31","author":[{"given":"Chaoyuan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoliang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"4168_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"4168_CR2","first-page":"421","volume":"15","author":"M Ding","year":"2023","unstructured":"Ding M, Zhou F, Li Y, Liu C, Gu Y, Wu J, et al. Cassiae Semen improves non-alcoholic fatty liver disease through autophagy-related pathway. Chin Herb Med. 2023;15:421\u20139.","journal-title":"Chin Herb Med"},{"key":"4168_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70132","volume":"8","author":"DM Miller","year":"2025","unstructured":"Miller DM, McCauley KF, Dunham-Snary KJ. Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinol Diabetes Metab. 2025;8:e70132.","journal-title":"Endocrinol Diabetes Metab"},{"key":"4168_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1439-0396.2007.00752.x","volume":"92","author":"P Nguyen","year":"2008","unstructured":"Nguyen P, Leray V, Diez M, Serisier S, Le Bloc\u2019h J, Siliart B, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr. 2008;92:272\u201383.","journal-title":"J Anim Physiol Anim Nutr"},{"key":"4168_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.116110","volume":"305","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Li X, Huang N, Li F, Ge J, Wang D, et al. Saikosaponins ameliorate hyperlipidemia in rats by enhancing hepatic lipid and cholesterol metabolism. J Ethnopharmacol. 2023;305:116110.","journal-title":"J Ethnopharmacol"},{"key":"4168_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","volume":"158","author":"N Gehrke","year":"2020","unstructured":"Gehrke N, Schattenberg JM. Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020;158:1929-1947.e6.","journal-title":"Gastroenterology"},{"key":"4168_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050641","volume":"58","author":"M Petrescu","year":"2022","unstructured":"Petrescu M, Vlaicu SI, Cium\u0103rnean L, Milaciu MV, M\u0103rginean C, Florea M, et al. Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina (Kaunas). 2022;58:641.","journal-title":"Medicina (Kaunas)"},{"key":"4168_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1550930","volume":"12","author":"SY Wang","year":"2025","unstructured":"Wang SY, Chen YS, Jin BY, Bilal A. The cGAS-STING pathway in atherosclerosis. Front Cardiovasc Med. 2025;12:1550930.","journal-title":"Front Cardiovasc Med"},{"key":"4168_CR9","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.2147\/DDDT.S521397","volume":"19","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang R, Cao Y, Li Y, Zhu Y, Zhang Z, et al. cGAS-STING targeting offers novel therapeutic opportunities in liver diseases. Drug Des Devel Ther. 2025;19:5835\u201353.","journal-title":"Drug Des Devel Ther"},{"key":"4168_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1139339","volume":"10","author":"H Li","year":"2023","unstructured":"Li H, Guo X, Aquino E, Wu C. Mini review: STING activation during non-alcoholic fatty liver disease. Front Nutr. 2023;10:1139339.","journal-title":"Front Nutr"},{"key":"4168_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.14218\/JCTH.2023.00197","volume":"12","author":"W Liu","year":"2024","unstructured":"Liu W, Zhang CZ, Yang C, Fan Y, Qiao L, Xie S, et al. Update on the STING signaling pathway in developing nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2024;12:91\u20139.","journal-title":"J Clin Transl Hepatol"},{"key":"4168_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682736","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Tian Y, Xia Q, Ke B. The cGAS-STING pathway: novel perspectives in liver diseases. Front Immunol. 2021;12:682736.","journal-title":"Front Immunol"},{"key":"4168_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.7150\/ijbs.84890","volume":"20","author":"J Gong","year":"2024","unstructured":"Gong J, Gao X, Ge S, Li H, Wang R, Zhao L. The role of cGAS-STING signalling in metabolic diseases: from signalling networks to targeted intervention. Int J Biol Sci. 2024;20:152\u201374.","journal-title":"Int J Biol Sci"},{"key":"4168_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41366-023-01272-x","volume":"47","author":"Y Qi","year":"2023","unstructured":"Qi Y, Wu Z, Chen D, Zhu L, Yang Y. A role of STING signaling in obesity-induced lung inflammation. Int J Obes (Lond). 2023;47:325\u201334.","journal-title":"Int J Obes (Lond)"},{"key":"4168_CR15","doi-asserted-by":"publisher","DOI":"10.21037\/tgh-20-125","volume":"6","author":"P Prasun","year":"2021","unstructured":"Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol-related liver disease. Transl Gastroenterol Hepatol. 2021;6:4.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"4168_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101241","volume":"15","author":"J Lv","year":"2022","unstructured":"Lv J, Xing C, Chen Y, Bian H, Lv N, Wang Z, et al. The STING in non-alcoholic fatty liver diseases: potential therapeutic targets in inflammation-carcinogenesis pathway. Pharmaceuticals (Basel). 2022;15:1241.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4168_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41577-022-00760-x","volume":"23","author":"S Marchi","year":"2023","unstructured":"Marchi S, Guilbaud E, Tait SWG, Yamazaki T, Galluzzi L. Mitochondrial control of inflammation. Nat Rev Immunol. 2023;23:159\u201373.","journal-title":"Nat Rev Immunol"},{"key":"4168_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100324","volume":"3","author":"R Chen","year":"2021","unstructured":"Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep. 2021;3:100324.","journal-title":"JHEP Rep"},{"key":"4168_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954129","volume":"13","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zou Y, Zhou X, Zhou J. Inhibitory targeting cGAS-STING-TBK1 axis: emerging strategies for autoimmune diseases therapy. Front Immunol. 2022;13:954129.","journal-title":"Front Immunol"},{"key":"4168_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1035441","volume":"2022","author":"P Semwal","year":"2022","unstructured":"Semwal P, Painuli S, Abu-Izneid T, Rauf A, Sharma A, Da\u015ftan SD, et al. Diosgenin: an updated pharmacological review and therapeutic perspectives. Oxid Med Cell Longev. 2022;2022:1035441.","journal-title":"Oxid Med Cell Longev"},{"key":"4168_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/biof.1815","volume":"48","author":"S Bandopadhyay","year":"2022","unstructured":"Bandopadhyay S, Anand U, Gadekar VS, Jha NK, Gupta PK, Behl T, et al. Dioscin: a review on pharmacological properties and therapeutic values. BioFactors. 2022;48:22\u201355.","journal-title":"BioFactors"},{"key":"4168_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106621","volume":"187","author":"M Yan","year":"2023","unstructured":"Yan M, Man S, Liang Y, Ma L, Guo L, Huang L, et al. Diosgenin alleviates nonalcoholic steatohepatitis through affecting liver-gut circulation. Pharmacol Res. 2023;187:106621.","journal-title":"Pharmacol Res"},{"key":"4168_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115388","volume":"412","author":"L Yu","year":"2021","unstructured":"Yu L, Lu H, Yang X, Li R, Shi J, Yu Y, et al. Diosgenin alleviates hypercholesterolemia via SRB1\/CES-1\/CYP7A1\/FXR pathway in high-fat diet-fed rats. Toxicol Appl Pharmacol. 2021;412:115388.","journal-title":"Toxicol Appl Pharmacol"},{"key":"4168_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175808","volume":"952","author":"S Chen","year":"2023","unstructured":"Chen S, Sun S, Feng Y, Li X, Yin G, Liang P, et al. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C\/PPAR\u03b1\/CD36 pathway. Eur J Pharmacol. 2023;952:175808.","journal-title":"Eur J Pharmacol"},{"key":"4168_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.gastrohep.2020.09.014","volume":"44","author":"Y He","year":"2021","unstructured":"He Y, Yang W, Gan L, Liu S, Ni Q, Bi Y, et al. Silencing HIF-1\u03b1 aggravates non-alcoholic fatty liver disease in vitro through inhibiting PPAR-\u03b1\/ANGPTL4 singling pathway. Gastroenterol Hepatol. 2021;44:355\u201365.","journal-title":"Gastroenterol Hepatol"},{"key":"4168_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.22751","volume":"49","author":"J Wu","year":"2009","unstructured":"Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009;49:1132\u201340.","journal-title":"Hepatology"},{"key":"4168_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-023-00567-4","volume":"17","author":"H Fukunaga","year":"2023","unstructured":"Fukunaga H, Ikeda A. Mitochondrial DNA copy number variation across three generations: a possible biomarker for assessing perinatal outcomes. Hum Genomics. 2023;17:113.","journal-title":"Hum Genomics"},{"key":"4168_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"4168_CR29","first-page":"3542","volume":"23","author":"CF Wang","year":"2019","unstructured":"Wang CF, Song CY, Wang X, Huang LY, Ding M, Yang H, et al. Protective effects of melatonin on mitochondrial biogenesis and mitochondrial structure and function in the HEK293-APPswe cell model of Alzheimer\u2019s disease. Eur Rev Med Pharmacol Sci. 2019;23:3542\u201350.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4168_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-025-08878-6","volume":"27","author":"C Song","year":"2025","unstructured":"Song C, Yin G, Wang L, Zhang F. Platycodin D attenuates behavioral deficits, amyloid-\u03b2 accumulation and mitochondrial impairment in AD models by inhibiting the cGAS-STING pathway. Neuromol Med. 2025;27:55.","journal-title":"Neuromol Med"},{"key":"4168_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","volume":"53","author":"X Zhang","year":"2020","unstructured":"Zhang X, Bai XC, Chen ZJ. Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity. 2020;53:43\u201353.","journal-title":"Immunity"},{"key":"4168_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22:63.","journal-title":"BMC Endocr Disord"},{"key":"4168_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"4168_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118182","volume":"260","author":"D Parama","year":"2020","unstructured":"Parama D, Boruah M, Yachna K, Rana V, Banik K, Harsha C, et al. Diosgenin, a steroidal saponin, and its analogs: effective therapies against different chronic diseases. Life Sci. 2020;260:118182.","journal-title":"Life Sci"},{"key":"4168_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1871523021666220328121721","volume":"21","author":"S Karami-Mohajeri","year":"2022","unstructured":"Karami-Mohajeri S, Mohammadinejad R, Ashrafizadeh M, Mohamadi N, Mohajeri M, Sharififar F. Diosgenin: mechanistic insights on its anti-inflammatory effects. Antiinflamm Antiallergy Agents Med Chem. 2022;21:2\u20139.","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"4168_CR36","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.devcel.2022.06.003","volume":"57","author":"R Donne","year":"2022","unstructured":"Donne R, Saroul-Ainama M, Cordier P, Hammoutene A, Kabore C, Stadler M, et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. Dev Cell. 2022;57:1728-1741.e6.","journal-title":"Dev Cell"},{"key":"4168_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.mito.2020.12.010","volume":"57","author":"S Ajaz","year":"2021","unstructured":"Ajaz S, McPhail MJ, Gnudi L, Trovato FM, Mujib S, Napoli S, et al. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion. 2021;57:119\u201330.","journal-title":"Mitochondrion"},{"key":"4168_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900942","volume":"65","author":"RCR Meex","year":"2021","unstructured":"Meex RCR, Blaak EE. Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD. Mol Nutr Food Res. 2021;65:e1900942.","journal-title":"Mol Nutr Food Res"},{"key":"4168_CR39","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348.","journal-title":"Metabolism"},{"key":"4168_CR40","first-page":"564","volume":"30","author":"CX Sha","year":"2022","unstructured":"Sha CX, Ju LL, Zhou P, Yao DF, Yao M. Activation of cGAS\/STING signaling pathway and its immunological role in the progression of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2022;30:564\u20138.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"4168_CR41","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1053\/j.gastro.2018.09.010","volume":"155","author":"X Luo","year":"2018","unstructured":"Luo X, Li H, Ma L, Zhou J, Guo X, Woo SL, et al. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. Gastroenterology. 2018;155:1971-1984.e4.","journal-title":"Gastroenterology"},{"key":"4168_CR42","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00535-021-01803-1","volume":"56","author":"C Chen","year":"2021","unstructured":"Chen C, Yang RX, Xu HG. STING and liver disease. J Gastroenterol. 2021;56:704\u201312.","journal-title":"J Gastroenterol"},{"key":"4168_CR43","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41401-023-01220-5","volume":"45","author":"XJ Li","year":"2024","unstructured":"Li XJ, Qu JR, Zhang YH, Liu RP. The dual function of cGAS-STING signaling axis in liver diseases. Acta Pharmacol Sin. 2024;45:1115\u201329.","journal-title":"Acta Pharmacol Sin"},{"key":"4168_CR44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/hep.29742","volume":"68","author":"CS Cho","year":"2018","unstructured":"Cho CS, Park HW, Ho A, Semple IA, Kim B, Jang I, et al. Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62\/sequestosome 1 phosphorylation. Hepatology. 2018;68:1331\u201346.","journal-title":"Hepatology"},{"issue":"1","key":"4168_CR45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-025-02253-4","volume":"10","author":"X Xu","year":"2025","unstructured":"Xu X, Pang Y, Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10(1):190.","journal-title":"Signal Transduct Target Ther"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04168-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:03:43Z","timestamp":1776089023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04168-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4168"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04168-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval committee of Shandong University of Traditional Chinese Medicine granted permission for the animal study (approval no: 2021-94).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"545"}}